Full-Time

QC Specialist 2

Analytical Investigations

Posted on 5/9/2026

PCI Pharma Services

PCI Pharma Services

1-10 employees

Pharmaceutical packaging and contract services

No salary listed

Bedford, NH, USA

In Person

Category
Biology & Biotech (1)
Requirements
  • Bachelor’s degree in Analytical Chemistry, Chemistry, Pharmaceutical Sciences, or related field
  • 2–5 years of QC Analytical Chemistry experience (pharma experience preferred)
  • Hands-on experience with UPLC, HPLC, GC, FTIR, UV/VIS, Karl Fischer, Particle Size Analyzer, Densitometer, and Osmometer
  • Solid understanding of cGMP, ICH, USP, and global compendia guidelines, especially in analytical method validation and stability studies
  • Strong organizational and documentation skills, technical writing ability, and excellent communication skills (written and verbal)
  • Ability to thrive in a fast-paced, dynamic environment, juggling multiple priorities while maintaining a sharp eye for detail
  • Proficiency in MS Office; experience with lab-based data management systems a plus
Responsibilities
  • Lead investigations into QC Analytical deviations, OOS/OOT/OOE results, and other quality issues
  • Serve as a key point of contact during audits and inspections, ensuring timely and compliant responses
  • Draft and revise change controls, technical reports, cGMP documents, and protocols
  • Perform QC analytical testing, review data, and identify trends to proactively address risks
  • Assist in managing analytical equipment to maintain compliance and efficiency
  • Collaborate cross-functionally to close out quality events and audit findings on time
  • Help shape and refine QC processes that support continuous improvement

PCI Pharma Services offers end-to-end pharmaceutical packaging and related services, including Folding Cartons, Labels, Contract Packaging, Clinical Services, and Brand Protection. It serves as a one-stop source for healthcare product developers and manufacturers, handling carton and label production, packaging operations, clinical services, and brand protection under one roof. The company stands out with eight decades of experience, strict cGMP and ISO compliance, lean manufacturing, ongoing R&D, and comprehensive employee training, security, hygiene, and inspection practices. Its goal is to be a trusted, end-to-end packaging partner that delivers reliable, compliant, and scalable packaging solutions, so clients can focus on their core business.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$4B

Headquarters

Burlington, Canada

Founded

1971

Simplify Jobs

Simplify's Take

What believers are saying

  • GLP-1 surge drives demand for PCI's prefilled syringes and autoinjectors.
  • Oncology-CNS pipelines favor PCI's patient-centric drug-device combinations.
  • Bain Capital's $10B valuation fuels $1B capacity expansions through 2028.

What critics are saying

  • San Diego isolator line delays to H1 2028 cede contracts to Lonza.
  • Novo Nordisk's Catalent acquisition slashes external CDMO fill-finish availability.
  • PE backers force divestitures if biotech funding dries post-2025.

What makes PCI Pharma Services unique

  • PCI integrates sterile fill-finish with drug-device assembly for end-to-end injectables.
  • Ajinomoto Althea acquisition adds rare US high-potent ADC sterile filling expertise.
  • AVI systems inspect 75 million vials annually, scaling quality without bottlenecks.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Company News

BioProcess International
Aug 15th, 2025
Building a better facility: BPI tours PCI manufacturing plant in Bedford

On the last day of June 2025's BIO conference in Boston, Massachusetts, contract development and manufacturing organization (CDMO) PCI Pharma Services bused a crowd of delegates to its manufacturing site in Bedford, New Hampshire where it hosted a tour of its 50,000 square-foot expansion.

Montgomery County
Jul 24th, 2025
PCI Pharma Services Valued at $10B

PCI Pharma Services in Northeast Philadelphia has received a multibillion-dollar investment from Bain Capital and Kohlberg, valuing the company at $10 billion. Kohlberg had previously invested in PCI, while Bain is a new investor. The investment will help PCI expand its services and geographic reach. The company currently operates 38 sites across seven countries and employs over 7,500 people.

JD Supra
Jul 16th, 2025
Healthcare & Life Sciences Private Equity Deal Tracker: Bain Capital and Kohlberg Invest in PCI Pharma

Healthcare & life sciences Private Equity deal tracker: Bain Capital and Kohlberg invest in PCI Pharma.

FinSMEs
Jul 15th, 2025
PCI Pharma Services Receives Investment from Mubadala, Bain Capital, and Kohlberg

PCI Pharma, a Philadelphia, PA-based contract development and manufacturing organization (CDMO) focused on biotherapies, received an investment from Bain Capital, Kohlberg, and Mubadala Investment Company.

MarketScreener
Jul 14th, 2025
PCI Pharma Services receives new funding

PCI Pharma Services announced it received a new round of funding on July 14, 2025. The funding was co-led by new investor Bain Capital, LP, and returning investor Kohlberg & Company, L.L.C. Additional participation came from returning investors Mubadala Investment Company PJSC and Partners Group Holding AG.